Securities Registration: Employee Benefit Plan (s-8)
20 May 2023 - 7:28AM
Edgar (US Regulatory)
As
filed with the Securities and Exchange Commission on May 19, 2023
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-8
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
ZYVERSA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
86-2685744 |
(State
or other jurisdiction of
incorporation or organization) |
|
(I.R.S.
Employer
Identification
No.) |
2200
N. Commerce Parkway, Suite 208
Weston,
FL 33326
(Address
of Principal Executive Offices) (Zip Code)
ZyVersa
Therapeutics, Inc. 2022 Omnibus Equity Incentive Plan
(Full
title of the plan)
Stephen
C. Glover
President
and Chief Executive Officer
ZyVersa
Therapeutics, Inc.
2200 N. Commerce Parkway, Suite 208
Weston,
FL 33326
(Name and address of agent for service)
Telephone:
(754) 231-1688
(Telephone
number, including area code, of agent for service)
Please
send copies of all communications to:
Michael
Lerner, Esq.
Jared
Kelly, Esq.
Lowenstein
Sandler LLP
1251 Avenue of the Americas
New York, New York 10020
Tel: (212) 262-6700
Indicate
by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller
reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
|
|
|
|
Non-accelerated filer |
☒ |
Smaller reporting company |
☒ |
|
|
|
|
|
|
Emerging growth company |
☒ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
PART
I
Information
Required in the Section 10(a) Prospectus
Item
1. Plan Information.
The
information called for by Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the “Registration Statement”)
and has been or will be sent or given to participating service providers in accordance with Rule 428 of the Securities Act of 1933, as
amended (the “Securities Act”), and the instructions to Form S-8. In accordance with the rules and regulations of the Securities
and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the
Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the
Securities Act.
Item
2. Registrant Information and Employee Plan Annual Information.
ZyVersa
Therapeutics, Inc., a Delaware corporation (the “Company”) will furnish without charge to each person to whom the prospectus
is delivered, upon the written or oral request of such person, a copy of any and all of the documents incorporated by reference into
this Registration Statement pursuant to Item 3 of Part II hereof, other than exhibits to such documents (unless such exhibits are specifically
incorporated by reference in such documents that are incorporated), and the other documents required to be delivered to eligible participants
in the Plan pursuant to Rule 428(b) under the Securities Act. Those documents are incorporated by reference in the Section 10(a) prospectus.
Requests should be directed to:
ZyVersa
Therapeutics, Inc.
2200
N. Commerce Parkway, Suite 208
Weston,
FL 33326
Attention:
Chief Financial Officer
Telephone:
(754) 231-1688
PART
II
Information
Required in the Registration Statement
Item
3. Incorporation of Documents by Reference.
The
following documents filed by the Company with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), are incorporated herein by reference:
|
(a) |
the Company’s
latest annual report on Form 10-K filed pursuant to Section 13(a) or 15(d) of the Exchange Act for the fiscal year ended December
31, 2022, as filed with the Commission on March 31, 2023; |
|
|
|
|
(b) |
The
Company’s quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2023, as filed with the Commission on
May 12, 2023; |
|
|
|
|
(c) |
The
Company’s current reports on Form 8-K filed with the Commission on January
6, 2023, January
27, 2023, January
27, 2023, March
3, 2023, March
10, 2023, April
3, 2023, May
15, 2023, and May 19, 2023 (other than any portions thereof deemed furnished and not filed); and |
|
|
|
|
(d) |
The
description of the Company’s common stock contained in the Company’s Form
8-A12B (Registration No. 001-41184) as filed with the Commission on December 20, 2021 pursuant to Section 12(b) of the Exchange
Act, as updated by the description of the Company’s capital stock contained in the Company’s registration statement
on Form S-1, as amended (File No. 333-269442) declared effective by the SEC on April 26, 2023, and the related prospectus, dated
April 26, 2023 filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended, including any amendments
or reports filed for the purpose of updating such description. |
All
documents filed by the Company pursuant to Section 13(a), 13(c), 14, or 15(d) of the Exchange Act subsequent to the filing of this Registration
Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or
which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement
and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein.
Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or
superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which
also is deemed to be incorporated by reference herein, modifies or supersedes such statement.
Item
4. Description of Securities.
Not
applicable.
Item
5. Interests of Named Experts and Counsel.
Not
applicable.
Item
6. Indemnification of Directors and Officers.
Section
145 of the Delaware General Corporation Law (the “DGCL”) provides, in general, that a corporation incorporated under the
laws of the State of Delaware, as we are, may indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding (other than a derivative action by or in the right of the corporation) by reason of the
fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another enterprise, against expenses (including attorneys’ fees), judgments,
fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding
if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the
corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was
unlawful. In the case of a derivative action, a Delaware corporation may indemnify any such person against expenses (including attorneys’
fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person
acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation,
except that no indemnification will be made in respect of any claim, issue or matter as to which such person will have been adjudged
to be liable to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or any other court
in which such action was brought determines such person is fairly and reasonably entitled to indemnity for such expenses.
As
permitted by the DGCL, our Second Amended and Restated Certificate of Incorporation (the “Charter”) contains provisions that
limit the liability of our directors for monetary damages for breach of fiduciary duties as a director, except liability for the following:
|
● |
any breach of the director’s
duty of loyalty to the Company or its stockholders; |
|
● |
acts or omissions not in good faith or that involve
intentional misconduct or a knowing violation of law; |
|
● |
as provided under Section 174 of the DGCL (regarding
unlawful dividends and stock purchases); or |
|
● |
any transaction from which the director derived an
improper personal benefit. |
This
limitation of liability does not apply to liabilities arising under the federal securities laws and does not affect the availability
of equitable remedies such as injunctive relief or rescission.
The
Charter and our Second Amended and Restated Bylaws (the “Bylaws”) provide that we will indemnify our directors, officers,
employees and agents to the extent and in the manner permitted by the provisions of the DGCL, as amended from time to time, subject to
any permissible expansion or limitation of such indemnification, as may be set forth in any amendment by stockholders or directors resolution.
Any repeal or modification of these provisions approved by our stockholders will be prospective only and will not adversely affect any
limitation on the liability of any of our directors or officers existing as of the time of such repeal or modification. The Bylaws also
permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her
actions in this capacity, regardless of whether the Bylaws would permit indemnification.
We
have entered into indemnification agreements with each of our directors and executive officers whereby we have agreed to indemnify those
directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in
legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director
or officer is or was a director, officer, employee or agent of the Company provided that such director or officer acted in good faith
and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interests of the Company.
Item
7. Exemption from Registration Claimed.
Not
applicable.
Item
8. Exhibits.
For
a list of exhibits, see the Exhibit Index in this Registration Statement, which is incorporated into this Item by reference.
EXHIBIT
INDEX
Exhibit
No. |
|
Exhibit |
|
|
|
4.1 |
|
Second Amended and Restated Certificate of Incorporation of ZyVersa Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2022). |
|
|
|
4.2 |
|
Second Amended and Restated Bylaws of ZyVersa Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2022). |
|
|
|
4.3 |
|
Certificate of Designation relating to the Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2022). |
|
|
|
4.4 |
|
Certificate of Designation relating to the Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.4 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2022). |
|
|
|
4.5 |
|
Specimen Class A Common Stock Certificate of ZyVersa Therapeutics, Inc. (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2022). |
|
|
|
5.1* |
|
Legal Opinion of Lowenstein Sandler LLP |
|
|
|
99.1 |
|
Variant Pharmaceuticals, Inc. 2014 Equity Compensation Plan (incorporated by reference to Exhibit 10.7 to the Company’s Form S-4 filed with the SEC on September 27, 2022). |
|
|
|
99.2 |
|
Amendment to Variant Pharmaceuticals, Inc. 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.20 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2022). |
|
|
|
99.3 |
|
ZyVersa Therapeutics, Inc. 2022 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.10 to the Company’s Current Report on Form 8-K filed with the SEC on December 13, 2022). |
|
|
|
99.4 |
|
Form of Incentive Stock Option Grant Agreement under the ZyVersa Therapeutics, Inc. 2022 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.6.1 to the Company’s Registration Statement on Form S-4 filed with the SEC on September 27, 2022). |
|
|
|
99.5 |
|
Form of Restricted Stock Unit Award Agreement under the ZyVersa Therapeutics, Inc. 2022 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.6.2 to the Company’s Registration Statement on Form S-4 filed with the SEC on September 27, 2022). |
|
|
|
99.6 |
|
Form of Non-Qualified Stock Option Grant Agreement under the ZyVersa Therapeutics, Inc. 2022 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.6.3 to the Company’s Registration Statement on Form S-4 filed with the SEC on September 27, 2022). |
|
|
|
23.1* |
|
Consent of Ernst & Young LLP. |
|
|
|
23.2* |
|
Consent of Lowenstein Sandler LLP (included as part of Exhibit 5.1). |
|
|
|
24.1* |
|
Power of Attorney (included on the signature page of this Registration Statement). |
|
|
|
107* |
|
Calculation of filing fee table. |
*
Filed herewith.
Item
9. Undertakings.
(a)
The undersigned Registrant hereby undertakes:
(1)
to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
|
(i) |
To include any prospectus required
by Section 10(a)(3) of the Securities Act of 1933; |
|
|
|
|
(ii) |
To reflect in the prospectus any facts or events arising
after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually
or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the
foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in
the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee”
table in the effective registration statement; and |
|
|
|
|
(iii) |
To include any material information with respect to
the plan of distribution not previously disclosed in the registration statement or any material change to such information in the
registration statement. |
Provided,
however, that Paragraphs (a)(1)(i) and (a)(1)(ii) of this section shall not apply if the information required to be included in a
post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant
to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in
the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof:
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(b)
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing
of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where
applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof.
(c)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Weston, Florida, on May 19, 2023.
|
ZyVersa Therapeutics, Inc. |
|
|
|
|
By: |
/s/ Stephen
C. Glover |
|
|
Stephen C. Glover |
|
|
President and Chief Executive Officer |
KNOW
ALL PERSONS BY THESE PRESENTS, that the undersigned officers and directors of ZyVersa Therapeutics, Inc., a Delaware corporation, do
hereby constitute and appoint each of Stephen C. Glover and Peter Wolfe as his or her true and lawful attorney-in-fact and agent, with
full power of substitution and re-substitution, for him and in his name, place, and stead, in any and all capacities, to sign any and
all amendments to this registration statement (including post-effective amendments to this Registration Statement on Form S-8), and to
file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary
to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming
all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on
behalf of the registrant in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/
Stephen C. Glover |
|
President, Chief Executive
Officer and Chairman |
|
May
19, 2023 |
Stephen C. Glover |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/
Peter Wolfe |
|
Chief Financial Officer
and Secretary |
|
May
19, 2023 |
Peter Wolfe |
|
(Principal Financial and
Accounting Officer) |
|
|
|
|
|
|
|
/s/
Robert G. Finizio |
|
Director |
|
May
19, 2023 |
Robert G. Finizio |
|
|
|
|
|
|
|
|
|
/s/
Min Chul Park, Ph.D. |
|
Director |
|
May
19, 2023 |
Min Chul Park, Ph.D. |
|
|
|
|
|
|
|
|
|
/s/
James Sapirstein |
|
Director |
|
May
19, 2023 |
James Sapirstein |
|
|
|
|
|
|
|
|
|
/s/
Gregory Frietag |
|
Director |
|
May
19, 2023 |
Gregory Frietag |
|
|
|
|
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Mar 2024 to Apr 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Apr 2023 to Apr 2024